153 related articles for article (PubMed ID: 38605434)
1. Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma.
Chandrasekhar S; Perez M; Niaz Z; Ekram J; Lal N; Koly S; Cao B; Zager JS; Alomar M
Cancer Control; 2024; 31():10732748241246898. PubMed ID: 38605434
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
[TBL] [Abstract][Full Text] [Related]
3. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
[TBL] [Abstract][Full Text] [Related]
6. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
[TBL] [Abstract][Full Text] [Related]
7. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
[TBL] [Abstract][Full Text] [Related]
8. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
Modi S; Gibson T; Vigneswaran G; Patel S; Wheater M; Karydis I; Gupta S; Takhar A; Pearce N; Ottensmeier C; Stedman B
Melanoma Res; 2022 Apr; 32(2):103-111. PubMed ID: 35254333
[TBL] [Abstract][Full Text] [Related]
9. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137
[TBL] [Abstract][Full Text] [Related]
10. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
[TBL] [Abstract][Full Text] [Related]
11. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
[TBL] [Abstract][Full Text] [Related]
12. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma.
Dewald CLA; Hinrichs JB; Becker LS; Maschke S; Meine TC; Saborowski A; Schönfeld LJ; Vogel A; Kirstein MM; Wacker FK
Rofo; 2021 Aug; 193(8):928-936. PubMed ID: 33535258
[TBL] [Abstract][Full Text] [Related]
13. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma.
Ben-Shabat I; Hansson C; Sternby Eilard M; Cahlin C; Rizell M; Lindnér P; Mattsson J; Olofsson Bagge R
J Vis Exp; 2015 Jan; (95):52490. PubMed ID: 25650893
[TBL] [Abstract][Full Text] [Related]
14. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.
Noter SL; Rothbarth J; Pijl ME; Keunen JE; Hartgrink HH; Tijl FG; Kuppen PJ; van de Velde CJ; Tollenaar RA
Melanoma Res; 2004 Feb; 14(1):67-72. PubMed ID: 15091197
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
[TBL] [Abstract][Full Text] [Related]
16. [Isolated liver perfusion with melphalan followed by pembrolizumab therapy for unresectable metastases of uveal melanoma to the liver].
Kaprin AD; Ivanov SA; Unguryan VM; Kazantsev AN; Belov YV
Khirurgiia (Mosk); 2023; (7):94-99. PubMed ID: 37379411
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations.
Miao N; Pingpank JF; Alexander HR; Steinberg SM; Beresneva T; Quezado ZM
Ann Surg Oncol; 2008 Mar; 15(3):815-23. PubMed ID: 18180999
[TBL] [Abstract][Full Text] [Related]
18. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
[TBL] [Abstract][Full Text] [Related]
19. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: a case series.
Fitzpatrick M; Richard Alexander H; Deshpande SP; Martz DG; McCormick B; Grigore AM
J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):647-51. PubMed ID: 24290749
[TBL] [Abstract][Full Text] [Related]
20. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.
van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C
Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
